VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Long-term effectiveness of levodopa-carbidopa intestinal gel in Parkinson’s disease

Angelo Antonini • 20 May 2020
EAN 2020
Movement Disorders Parkinson's Disease Carbidopa Levodopa
Treatment

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease (PD) on the Italian GLORIA patient population. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Angelo Antonini

2:58
Increasing mobility in patients with Parkinson’s disease during COVID-19
Angelo Antonini • 29 Mar 2022
2:00
Adjunctive MAO-B or COMT inhibitors to optimize levodopa treatment in PD
Angelo Antonini • 26 Jun 2022
2:35
Levodopa dose adjustment versus adjunctive therapy in Parkinson’s disease
Angelo Antonini • 26 Jun 2022
2:48
The emergence of COVID-19-induced parkinsonism
Angelo Antonini • 29 Mar 2022

Related Videos

17:52
Neuromodulation of freezing in Parkinson's disease
Alfonso Fasano • 7 Sep 2023
2:08
The future of neuromodulation in movement disorders
Alfonso Fasano • 7 Sep 2023
1:42
The importance of partnerships between healthcare professionals and Parkinson’s disease patients
Alfonso Fasano • 7 Sep 2023
2:11
Ambroxol effects in glucocerebrosidase: potential use in Parkinson's disease
Stephen Pasternak • 29 Aug 2023
The content of VJNeurology is intended for healthcare professionals